Exposure-response relationship during vedolizumab induction therapy in adults with ulcerative colitis

被引：0
|
作者：
Rosario, M. [1 ]
French, J. [2 ]
Dirks, N. [2 ]
Milton, A. [1 ]
Fox, I. [1 ]
Gastonguay, M. [2 ]
机构：
[1] Takeda Pharmaceut Int Co, Clin Pharmacol, Cambridge, MA USA
[2] Metrum Res Grp LLC, Biotechnol, Tariffville, CT USA
来源：
JOURNAL OF CROHNS & COLITIS | 2014年 / 8卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P489
引用
收藏
页码：S270 / S271
页数：3
相关论文
共 50 条
  • [31] VEDOLIZUMAB, USTEKINUMAB AND TOFACITINIB AS TRIPLE THERAPY FOR ULCERATIVE COLITIS
    Thurston, Theresa
    Moskow, Joshua
    Glassner, Kerri
    Abraham, Bincy
    INFLAMMATORY BOWEL DISEASES, 2023, 29 : S81 - S81
  • [32] VEDOLIZUMAB, USTEKINUMAB AND TOFACITINIB AS TRIPLE THERAPY FOR ULCERATIVE COLITIS
    Thurston, Theresa
    Moskow, Joshua
    Glassner, Kerri
    Abraham, Bincy
    GASTROENTEROLOGY, 2023, 164 (04) : S104 - S104
  • [33] Exposure-response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease
    Vande Casteele, N.
    Feagan, B. G.
    Vermeire, S.
    Yassine, M.
    Coarse, J.
    Kosutic, G.
    Sandborn, W. J.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 47 (02) : 229 - 237
  • [34] Exposure-response relationships of etrolizumab in patients with moderately-to-severely active ulcerative colitis
    Kassir, Nastya
    Zhu, Rui
    Moein, Anita
    Langenhorst, Jurgen
    Ribbing, Jakob
    Zhang, Rong
    Tang, Meina T.
    Oh, Young S.
    Zhang, Wenhui
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2022, 11 (09): : 1234 - 1243
  • [35] Mirikizumab pharmacokinetics and exposure-response in pediatric patients with moderate-to-severe ulcerative colitis
    Otani, Yuki
    Chua, Laiyi
    Komocsar, Wendy J.
    Larkin, Amy
    Johns, Jordan
    Zhang, Xin
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2025, 14 (03): : 474 - 485
  • [36] Pharmacokinetics and exposure-response of tofacitinib in a Phase 3 maintenance study in ulcerative colitis patients
    Mukherjee, A.
    D'Haens, G. R.
    Sandborn, W. J.
    Tsuchiwata, S.
    Vong, C.
    Deng, C.
    Xie, R.
    Hazra, A.
    Martin, S. W.
    Friedman, G.
    Niezychowski, W.
    Su, C.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S69 - S70
  • [37] Assessment of Adalimumab Dose Selection for Adult Ulcerative Colitis Using Exposure-Response Analyses
    Bewernitz, Michael
    Garnett, Christine
    Gottlieb, Klaus
    Krudys, Kevin
    Mulberg, Andrew E.
    Johnson, Aisha P.
    Rajpal, Anil
    Wang, Yow-Ming
    Zhou, Lin
    Bugin, Kevin
    Mehrotra, Nitin
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2013, 40 : S44 - S45
  • [38] PHARMACOKINETICS AND EXPOSURE-RESPONSE OF TOFACITINIB IN A PHASE 3 MAINTENANCE STUDY IN ULCERATIVE COLITIS PATIENTS
    Mukherjee, Arnab
    D'Haens, Geert R.
    Sandborn, William J.
    Tsuchiwata, Shinichi
    Vong, Camille
    Deng, Chenhui
    Xie, Rujia
    Hazra, Anasuya
    Martin, Steven W.
    Friedman, Gary
    Niezychowski, Wojciech
    Su, Chinyu
    GASTROENTEROLOGY, 2017, 152 (05) : S595 - S596
  • [39] Relationship between vedolizumab serum concentrations in the induction phase and early and sustained response in the first year of treatment in patients with ulcerative colitis
    German Sanchez-Hernandez, Jose
    Rebollo, Noemi
    Munoz, Fernando
    Padulles-Zamora, Nuria
    Miarons, Marta
    Martin Gutierrez, Nerea
    Martin Gil, Marcos
    Jose Otero, Maria
    FARMACIA HOSPITALARIA, 2021, 45 : 38 - 44
  • [40] Tofacitinib plasma concentration monitoring is not needed for optimisation of induction therapy in moderate-to-severe ulcerative colitis: results of pooled exposure-response analyses of Phase 3 induction studies
    Mukherjee, A.
    Tsuchiwata, S.
    Deng, C.
    Vong, C.
    Xie, R.
    Martin, S. W.
    Yu, D.
    Woodworth, D.
    Niezychowski, W.
    Su, C.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S73 - S74
12345